Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Change in Account Payables: 2019-2024

Historic Change in Account Payables for Lyell Immunopharma (LYEL) over the last 6 years, with Dec 2024 value amounting to -$3.2 million.

  • Lyell Immunopharma's Change in Account Payables fell 37.15% to -$779,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.7 million, marking a year-over-year decrease of 508.02%. This contributed to the annual value of -$3.2 million for FY2024, which is 320.90% down from last year.
  • Lyell Immunopharma's Change in Account Payables amounted to -$3.2 million in FY2024, which was down 320.90% from $1.5 million recorded in FY2023.
  • In the past 5 years, Lyell Immunopharma's Change in Account Payables ranged from a high of $1.5 million in FY2023 and a low of -$3.2 million during FY2024.
  • For the 3-year period, Lyell Immunopharma's Change in Account Payables averaged around -$367,667, with its median value being $667,000 (2022).
  • Its Change in Account Payables has fluctuated over the past 5 years, first skyrocketed by 632.97% in 2022, then crashed by 320.90% in 2024.
  • Lyell Immunopharma's Change in Account Payables (Yearly) stood at -$278,000 in 2020, then soared by 132.73% to $91,000 in 2021, then soared by 632.97% to $667,000 in 2022, then surged by 119.49% to $1.5 million in 2023, then tumbled by 320.90% to -$3.2 million in 2024.